

Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1. (Withdrawn) A method of treating a patient suffering from substance abuse comprising administering to the patient medication that includes a dose of clozapine, risperidone or both, effective to reduce abuse.
2. (Withdrawn) A method of treating a patient suffering from substance abuse comprising administering to the patient medication effective to strongly antagonize  $\alpha_2$  adrenergic receptors and to weakly antagonize dopamine D2 receptors.
3. (Withdrawn) A method of treating, a patient suffering from substance abuse comprising administering to the patient medication effective to rectify an abuse-associated dysfunction in the DA-mediated brain reward circuit.
4. (Withdrawn) The method of any one of claims 1-3 in which the patient is not schizophrenic.
5. (Withdrawn) The method of any one of claims 1-3 in which the medication comprises clozapine.
6. (Withdrawn) The method of claim 3 in which the medication comprises:  
a first component which weakly blocks the D2 receptor; and  
a second component which strongly blocks  $\alpha_2$  receptors.

7. (Withdrawn) The method of claim 6 in which the first component is selected from clozapine, risperidone, olanzapine, quetiapine and ziprasidone.
8. (Withdrawn) The method of claim 6 or 7 in which the second component is idazoxan, or another  $\alpha$ 2 receptor antagonist.
9. (Withdrawn) The method of claim 2 in which the medication is formulated as a single dose comprising both the first and the second components.
10. (Withdrawn) The method of claim 2 or 3 in which the medication is characterized by a ratio of  $\alpha$ 2 blockade: D2 receptor blockade similar to that of clozapine.
11. (Withdrawn) The method of claim 10 in which the medication is characterized by a ratio of  $\alpha$ 2C blockade: D2 receptor blockade similar to that of clozapine.
12. (Withdrawn) The method of claim 6 in which the medication strongly blocks the  $\alpha$ 2C receptor.
13. (Original) A cocktail comprising
  - a first component which weakly blocks the D2 receptor; and
  - a strong  $\alpha$ 2 receptor antagonist.
14. (Previously Presented) The cocktail of claim 13 in which the first component is selected from clozapine, risperidone, olanzapine, quetiapine and ziprasidone.
15. (Previously Presented) The cocktail of claim 13 or 14 in which the second component is idazoxan, or another  $\alpha$ 2 receptor antagonist.

16. (Previously Presented) The cocktail of claim 13 or 14 in which the cocktail is characterized by strong blockade of the  $\alpha$ 2C receptor.
17. (Previously Presented) The cocktail of claim 13 or 14 in which the cocktail is characterized by a ratio of  $\alpha$ 2 blockade: D2 receptor blockade similar to that of clozapine.
18. (Withdrawn) The method claim 12 in which the cocktail is characterized by a ratio of  $\alpha$ 2C blockade: D2 receptor blockade similar to that of clozapine.
19. (Withdrawn) The method of any one of claims 1-3 wherein the substance is alcohol.
20. (New) The cocktail of claim 13 comprising idazoxan.
21. (New) The cocktail of claim 13 comprising quetiapine.
22. (New) The cocktail of claim 13 comprising idazoxan and quetiapine.